- Home
- HSDT vs QNRX Comparison
HSDT vs QNRX Comparison
Compare HSDT & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSDT
- QNRX
- Stock Information
- Founded
- HSDT N/A
- QNRX 2018
- Country
- HSDT United States
- QNRX United States
- Employees
- HSDT N/A
- QNRX N/A
- Industry
- HSDT Biotechnology: Electromedical & Electrotherapeutic Apparatus
- QNRX Medical/Dental Instruments
- Sector
- HSDT Health Care
- QNRX Health Care
- Exchange
- HSDT Nasdaq
- QNRX Nasdaq
- Market Cap
- HSDT 4.3M
- QNRX 4.2M
- IPO Year
- HSDT N/A
- QNRX N/A
- Fundamental
- Price
- HSDT $6.12
- QNRX $7.38
- Analyst Decision
- HSDT Hold
- QNRX
- Analyst Count
- HSDT 1
- QNRX 0
- Target Price
- HSDT N/A
- QNRX N/A
- AVG Volume (30 Days)
- HSDT 40.5K
- QNRX 3.2K
- Earning Date
- HSDT 08-14-2025
- QNRX 08-07-2025
- Dividend Yield
- HSDT N/A
- QNRX N/A
- EPS Growth
- HSDT N/A
- QNRX N/A
- EPS
- HSDT N/A
- QNRX N/A
- Revenue
- HSDT $295,000.00
- QNRX N/A
- Revenue This Year
- HSDT N/A
- QNRX N/A
- Revenue Next Year
- HSDT $75.13
- QNRX N/A
- P/E Ratio
- HSDT N/A
- QNRX N/A
- Revenue Growth
- HSDT N/A
- QNRX N/A
- 52 Week Low
- HSDT $5.37
- QNRX $5.01
- 52 Week High
- HSDT $1,200.00
- QNRX $54.95
- Technical
- Relative Strength Index (RSI)
- HSDT 28.22
- QNRX 47.26
- Support Level
- HSDT $5.90
- QNRX $7.30
- Resistance Level
- HSDT $6.57
- QNRX $7.64
- Average True Range (ATR)
- HSDT 0.37
- QNRX 0.22
- MACD
- HSDT 1.15
- QNRX 0.08
- Stochastic Oscillator
- HSDT 45.19
- QNRX 43.37
About HSDT Helius Medical Technologies Inc. (DE)
Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license, or acquire non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's product, known as the Portable Neuromodulation Stimulator (PoNS) is authorized for sale in Canada as a class II, a non-implantable medical device intended for use as a short-term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with supervised therapeutic exercise.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.